Satoris

By Adam Bonislawski
A Stanford University-led research team has identified plasma proteins linked to declines in neurogenesis and impaired learning and memory.

RBM acquired biomarker-related IP for Alzheimer's disease and other central nervous system conditions.

Satoris will use a panel of 500 signaling proteins and antibody-based quantitative nitrocellulose filter membrane array technology to search for candidate biomarkers for the disease. In May, it launched its first commercial products, protein panels for Alzheimer's disease and dementia.

According to Satoris, the 189-marker panel covers the "most physiologically relevant pathways and includes biomarkers known to be important in the major disease processes for drug development … [and] and thus provide researchers with critical biological information plus leads for further study."

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.